文献速递妇科

2007至2020年妇科临床试验的早期终止、结果报告与发表情况

Early Discontinuation, Results Reporting, and Publication of Gynecology Clinical Trials From 2007 to 2020.
PubMed 文献 · Obstet Gynecol · 2022-04-05

该横断面分析纳入ClinicalTrials.gov上2007年10月至2020年3月注册的223,690项试验,其中仅3.7%(n=8,174,约3,759,086名参与者)为妇科试验。完成试验中仅42.0%通过结果报告和发表传播结果。产业资助试验最可能早期终止(P<.001),学术资助试验最不可能报告结果(aOR 0.38,95%CI 0.30-0.50)但最可能发表(aOR 1.62,95%CI 1.24-2.12)。

要点

  • 妇科试验仅占所有临床试验的3.7%。
  • 完成试验中仅42.0%同时报告结果并发表。
  • 生殖内分泌与不孕症试验增长最快(增长率6.4%),但最可能早期终止(aHR 2.08,95%CI 1.59-2.71)。

核心结论

  • 妇科临床试验仅占所有临床试验的3.7%,完成试验的结果传播情况差, findings raise concern about bias in the performance, reporting, and publication of gynecology clinical trials。

研究设计与样本

  • 对2007年至2020年在ClinicalTrials.gov注册的所有妇科试验及其发表文献进行横断面分析,采用描述性、多变量logistic和Cox回归分析,主要暴露变量为试验资助来源和亚专业。

主要发现

  • 在2007年10月至2020年3月注册的223,690项试验中,妇科试验仅3.7%(n=8,174,约3,759,086名参与者)。
  • 亚专业包括生殖内分泌与不孕症(n=1,428,17.5%)、妇科肿瘤(n=2,063,25.2%)、泌尿妇科(n=1,118,13.7%)、计划生育(n=648,7.9%)和其他良性妇科(n=2,917,35.7%)。
  • 完成试验中仅42.0%通过结果报告和发表传播结果。
  • 产业资助试验最可能早期终止(P<.001);学术资助试验最不可能报告结果(aOR 0.38,95%CI 0.30-0.50)但最可能发表(aOR 1.62,95%CI 1.24-2.12)。
  • 生殖内分泌与不孕症试验在2007至2020年间增长最快(增长率6.4%),且与计划生育试验最可能早期终止(生殖内分泌与不孕症:aHR 2.08,95%CI 1.59-2.71;计划生育:aHR 1.55,95%CI 1.06-2.25);完成时生殖内分泌与不孕症试验最不可能报告结果(aOR 0.58,95%CI 0.38-0.88);亚专业间发表无显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To characterize gynecology clinical trials over time, compare gynecology subspecialties, and analyze factors associated with early discontinuation, results reporting, and publication. METHODS: We conducted a cross-sectional analysis of all gynecology trials registered on ClinicalTrials.gov between 2007 and 2020 and their resulting publications. Trials were analyzed with descriptive, multivariable logistic, and Cox regression analyses. Primary exposure variables were trial funding and subspecialty. The three primary outcomes included early discontinuation, results reporting to ClinicalTrials.gov, and publication in a peer-reviewed journal indexed on PubMed. RESULTS: Of 223,690 trials registered on ClinicalTrials.gov between October 2007 and March 2020, only 3.7% focused on gynecology (n=8,174, approximately 3,759,086 participants). Subspecialties included reproductive endocrinology and infertility (n=1,428, 17.5%), gynecologic oncology (n=2,063, 25.2%), urogynecology (n=1,118, 13.7%), family planning (n=648, 7.9%), and other benign gynecology (n=2,917, 35.7%). Only 42.0% of completed trials disseminated results through results reporting and publication. Of all funding types, industry-funded trials were the most likely to be discontinued early (P<.001). Academic-funded trials were the least likely to report results (adjusted odds ratio [aOR] 0.38, 95% CI 0.30-0.50) but the most likely to publish (aOR 1.62, 95% CI 1.24-2.12). The number of reproductive endocrinology and infertility trials increased the most of any subspecialty between 2007 and 2020 (6.4% growth rate). Reproductive endocrinology and infertility and family planning trials were the most likely to be stopped early (reproductive endocrinology and infertility: adjusted hazard ratio [aHR] 2.08, 95% CI 1.59-2.71; family planning: aHR 1.55 95% CI 1.06-2.25). When completed, reproductive endocrinology and infertility trials were the least likely to report results (aOR 0.58, 95% CI 0.38-0.88). No significant differences were seen between subspecialties with respect to publication. CONCLUSION: Gynecology trials comprise only 3.7% of all clinical trials. The paucity of gynecology clinical trials aligns with decades of female underrepresentation in research. When completed, gynecology trials have poor dissemination. Our findings raise concern about bias in the performance, reporting, and publication of gynecology clinical trials.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Steinberg JR, Magnani CJ, Turner BE, et al. Early Discontinuation, Results Reporting, and Publication of Gynecology Clinical Trials From 2007 to 2020. Obstet Gynecol. 2022. PMID: 35576341. doi:10.1097/AOG.0000000000004735

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。